You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 29, 2024

Details for Patent: 11,382,926


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 11,382,926 protect, and when does it expire?

Patent 11,382,926 protects VEKLURY and is included in one NDA.

Protection for VEKLURY has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has fifty-two patent family members in twenty-three countries.

Summary for Patent: 11,382,926
Title:Methods for treating Arenaviridae and Coronaviridae virus infections
Abstract: Provided are methods for treating Arenaviridae and Coronaviridae virus infections by administering nucleosides and prodrugs thereof, of Formula I: ##STR00001## wherein the 1' position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are particularly useful for the treatment of Lassa virus and Junin virus infections.
Inventor(s): Clarke; Michael O'Neil Hanrahan (Redwood City, CA), Feng; Joy Yang (Hillsborough, CA), Jordan; Robert (Foster City, CA), Mackman; Richard L. (Millbrae, CA), Ray; Adrian S. (Burlingame, CA), Siegel; Dustin (Half Moon Bay, CA)
Assignee: Gilead Sciences, Inc. (Foster City, CA)
Application Number:17/222,066
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 11,382,926

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Gilead Sciences Inc VEKLURY remdesivir POWDER;INTRAVENOUS 214787-001 Oct 22, 2020 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Gilead Sciences Inc VEKLURY remdesivir SOLUTION;INTRAVENOUS 214787-002 Oct 22, 2020 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 11,382,926

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2016323604 ⤷  Try a Trial
Australia 2020233714 ⤷  Try a Trial
Australia 2023200990 ⤷  Try a Trial
Brazil 112018005048 ⤷  Try a Trial
Brazil 122020020217 ⤷  Try a Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.